Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 gemcitabine + docetaxel for advanced bone and soft tissue sarcomas
jRCTs051180042Phase 2Recruiting
- Start
- Mar 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and docetaxel in bone cancer and soft tissue sarcoma (STS). Primary endpoint: progression-free survival. Started Mar 2019; status: recruiting.
02
Drugs
gemcitabinedocetaxel
03
Conditions
bone cancersoft tissue sarcoma (STS)
Beyond the preview
Go deeper on jRCTs051180042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180042.